These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 20629223)

  • 1. Vascular reactivity in diabetes mellitus.
    Dandona P
    Endocrinol Nutr; 2009 Dec; 56 Suppl 4():12-4. PubMed ID: 20629223
    [No Abstract]   [Full Text] [Related]  

  • 2. Endothelial dysfunction and its role in diabetic vascular disease.
    Hartge MM; Kintscher U; Unger T
    Endocrinol Metab Clin North Am; 2006 Sep; 35(3):551-60, viii-ix. PubMed ID: 16959585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the endothelium to prevent diabetes-related atherosclerosis.
    Kearney MT
    Diab Vasc Dis Res; 2010 Jul; 7(3):177. PubMed ID: 20699387
    [No Abstract]   [Full Text] [Related]  

  • 4. Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus.
    Otsuki M; Goya K; Kasayama S
    Vasc Health Risk Manag; 2005; 1(3):209-15. PubMed ID: 17319106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetic angiopathy: tracking down the culprits.
    Tooke JE; Shore AC; Cohen RA; Kluft C
    J Diabetes Complications; 1996; 10(3):173-81. PubMed ID: 8807468
    [No Abstract]   [Full Text] [Related]  

  • 6. Is insulin resistance atherogenic? Possible mechanisms.
    Defronzo RA
    Atheroscler Suppl; 2006 Aug; 7(4):11-5. PubMed ID: 16815101
    [No Abstract]   [Full Text] [Related]  

  • 7. The distinctive nature of atherosclerotic vascular disease in diabetes: pathophysiological and morphological insights.
    Puri R; Kataoka Y; Uno K; Nicholls SJ
    Curr Diab Rep; 2012 Jun; 12(3):280-5. PubMed ID: 22492060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Microcirculation in diabetes: implications for chronic complications and treatment of the disease].
    Aguiar LG; Villela NR; Bouskela E
    Arq Bras Endocrinol Metabol; 2007 Mar; 51(2):204-11. PubMed ID: 17505627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time course of endothelial dysfunction in diabetes mellitus.
    Wascher TC; Graier WF; Bahadori B; Toplak H
    Circulation; 1994 Aug; 90(2):1109-10. PubMed ID: 8044928
    [No Abstract]   [Full Text] [Related]  

  • 10. Thiazolidinediones-improving endothelial function and potential long-term benefits on cardiovascular disease in subjects with type 2 diabetes.
    Dandona P; Ghanim H; Chaudhuri A; Mohanty P
    J Diabetes Complications; 2008; 22(1):62-75. PubMed ID: 18191079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired vascular nitric oxide bioactivity in women with previous gestational diabetes.
    Pleiner J; Mittermayer F; Langenberger H; Winzer C; Schaller G; Pacini G; Kautzky-Willer A; Tura A; Wolzt M
    Wien Klin Wochenschr; 2007; 119(15-16):483-9. PubMed ID: 17721768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haematocrit, type 2 diabetes, and endothelium-dependent vasodilatation of resistance vessels.
    Natali A; Toschi E; Baldeweg S; Casolaro A; Baldi S; Sironi AM; Yudkin JS; Ferrannini E
    Eur Heart J; 2005 Mar; 26(5):464-71. PubMed ID: 15691863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Troglitazone-induced changes in adiponectin do not affect endothelial function in diabetes.
    Buras J; Reenstra WR; Orlow D; Horton ES; Veves A
    Obes Res; 2005 Jul; 13(7):1167-74. PubMed ID: 16076985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitric oxide and vascular responses in Type I diabetes.
    Chan NN; Vallance P; Colhoun HM
    Diabetologia; 2000 Feb; 43(2):137-47. PubMed ID: 10753034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The endothelium and vascular inflammation in diabetes.
    Hartge MM; Unger T; Kintscher U
    Diab Vasc Dis Res; 2007 Jun; 4(2):84-8. PubMed ID: 17654441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelial dysfunction in patients with type 2 diabetes and the effects of thiazolidinedione antidiabetic agents.
    Dandona P; Aljada A
    J Diabetes Complications; 2004; 18(2):91-102. PubMed ID: 15120703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current perspective. Diabetic vascular disease: from endothelial dysfunction to atherosclerosis.
    Candido R; Zanetti M
    Ital Heart J; 2005 Sep; 6(9):703-20. PubMed ID: 16212072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of pioglitazone on endothelial function in impaired glucose tolerance.
    Quinn CE; Lockhart CJ; Hamilton PK; Loughrey CM; McVeigh GE
    Diabetes Obes Metab; 2010 Aug; 12(8):709-15. PubMed ID: 20590748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
    Sorrentino SA; Bahlmann FH; Besler C; Müller M; Schulz S; Kirchhoff N; Doerries C; Horváth T; Limbourg A; Limbourg F; Fliser D; Haller H; Drexler H; Landmesser U
    Circulation; 2007 Jul; 116(2):163-73. PubMed ID: 17592079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes.
    Lehmann DF; Lohray BB
    J Clin Pharmacol; 2008 Aug; 48(8):999-1002. PubMed ID: 18650500
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.